Fidelity MSCI Health Care Index ETF
FIDELITY COVINGTON TRUST · 1 share class
Fund classification
Classified from what the fund holds · as of 2026 Q2
Fidelity MSCI Health Care Index ETF is a U.S. equity index ETF that tracks the MSCI USA IMI Health Care 25/50 Index. 20% of FHLC’s stock holdings are in companies whose revenue grew in the top quartile of U.S. companies over the last five fiscal years (covering 95% of the fund’s equity).
- Asset class
- Equity
- Region
- United States
- Management
- Index (passive)
- Fund type
- ETF
- Features
- Non-diversified
Fund profile
As filed in the prospectus · 2025 Q4
Fidelity MSCI Health Care Index ETF seeks to provide investment returns that correspond, before fees and expenses, generally to the performance of the MSCI USA IMI Health Care 25/50 Index.
The fund tracks the MSCI USA IMI Health Care 25/50 Index, which comprises U.S. health care companies classified by GICS, including equipment and service providers as well as pharmaceutical and biotechnology firms. It uses representative sampling, holding a subset of index securities selected to match the index's overall investment and fundamental characteristics rather than all constituents. Because the fund may not hold all securities in the index, its returns may diverge from the index.
| Share class | Expense ratio |
|---|---|
| FHLC | 0.08% |
Portfolio turnover 3.00% · as of 2025 Q4
Allocation
Asset groups · long / short shown separately, never netted · 2026 Q2
| Stocks | 99.64% |
| Cash & short-term | 0.23% |
| Derivatives | -0.00% |
The outer band is exposure held short — written against the portfolio rather than part of it, which is why it sits outside the ring and why the two are never netted into one figure.
Derivatives are shown at market value, not notional exposure.
Sector allocation
The same holdings as Allocation above, grouped by market sector instead of asset type · as of 2026 Q2
| Health Care | 97.4% |
| International | 2.4% |
| Cash | 0.2% |
| Industrials | 0.0% |
| Other | 0.0% |
Government, Securitized and Cash are non-corporate buckets; International is foreign holdings we don’t sector-classify, and Other is the residual (held funds, unresolved names).
Portfolio growth profile
How much of the fund’s stock holdings are in fast-growing companies · as of 2026 Q2
Share of the fund’s equity (by value) in companies whose trailing five-year revenue — or net-income — growth ranks in the top 25% of U.S. public companies. Foreign and newly-listed holdings are excluded, so the figure covers only part of the book. From SEC filings — not investment advice. How we measure this.
Latest quarter
What changed since the fund's previous filing
Largest new: Terns Pharmaceuticals Inc, ERAS, CAPR, ALMS, KOD, EYPT, BFLY, UroGen Pharma Ltd
Largest exited: Exact Sciences Corp, Hologic Inc, Avidity Biosciences Inc, Amicus Therapeutics Inc, Arcellx Inc, Avadel Pharmaceuticals PLC, Dynavax Technologies Corp, Day One Biopharmaceuticals Inc
Return profile
Total return as filed — price change plus distributions reinvested · trailing figures to Apr 2026
Holdings
By % of NAV · equity positions carry filed share counts · every resolvable issuer links to its company page
| Ticker | Issuer | %NAV | Reported price | Value | Shares |
|---|---|---|---|---|---|
| LLY | Eli Lilly & CoLLY | 12.13% | $934.60 | $346.22M | 370.4K |
| JNJ | Johnson & JohnsonJNJ | 8.94% | $229.85 | $255.28M | 1.1M |
| ABBV | AbbVie IncABBV | 6.03% | $211.32 | $172.17M | 814.8K |
| UNH | UnitedHealth Group IncUNH | 5.42% | $370.48 | $154.71M | 417.6K |
| MRK | Merck & Co IncMRK | 4.38% | $109.18 | $124.92M | 1.1M |
| AMGN | Amgen IncAMGN | 3.01% | $346.25 | $85.95M | 248.2K |
| TMO | Thermo Fisher Scientific IncTMO | 2.91% | $478.96 | $82.96M | 173.2K |
| GILD | Gilead Sciences IncGILD | 2.62% | $130.84 | $74.83M | 571.9K |
| ISRG | Intuitive Surgical IncISRG | 2.62% | $457.61 | $74.79M | 163.4K |
| ABT | Abbott LaboratoriesABT | 2.55% | $90.79 | $72.78M | 801.6K |
Reported price is the fund's own reported value divided by its own reported shares at 2026-04-30 — not a live quote, and not what the fund paid.
Top 10 positions are 50.61% of net assets, top 25 73.42%, across 338 issuers.
See more of this fund's book
More positions with filed share counts, and the quarter-over-quarter change list rather than the largest few — free with an account, no card required.
Sign in free